Cargando…
Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy
RATIONALE: Regorafenib represents a treatment option in heavily pretreated patients affected by metastatic colorectal cancer (mCRC). Its safety profile is typical of small-molecule tyrosine-kinase inhibitors (TKIs) and most adverse events are manageable. PATIENT CONCERNS: A 56 years-old Caucasian ma...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406055/ https://www.ncbi.nlm.nih.gov/pubmed/28422839 http://dx.doi.org/10.1097/MD.0000000000006522 |